New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:28 EDTJNJ, LH, DHR, DGX, RHHBY, ABTCLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Piper Jaffray views the Centers for Medicare & Medicaid Services' plan to revalue Clinical Lab Fee Schedule test codes as a potential negative for Quest Diagnostics (DGX) and LabCorp (LH) as well as diagnostic manufacturers like Abbott (ABT), Danaher (DHR), Johnson & Johnson (JNJ) and Roche (RHHBY). Piper says Quest and LabCorp both have around 12% of revenue exposure to CLFS, which it feels presents risk for additional reimbursement pressure in FY15. The review follows an Office of Inspector General report that found CMS paid between 18%-30% higher for 20 high volume/high expenditure tests than state and federal plans.
News For DGX;LH;ABT;DHR;JNJ;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
10:02 EDTJNJWi-LAN enters settlement, license agreement with Cordis
Subscribe for More Information
July 5, 2015
13:58 EDTRHHBYSome European stocks still look appealing amid Greek uncertainty, Barron's says
Subscribe for More Information
July 1, 2015
16:33 EDTJNJGilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gileadís emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naÔve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDAís acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gileadís Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
19:32 EDTDGXQuest to acquire MemorialCare's laboratory outreach service business
Quest Diagnostics and MemorialCare Health System announced they have entered into a definitive agreement for Quest to acquire MemorialCare Health System's laboratory outreach service business. The transaction is expected to be neutral to earnings in 2015. Quest and MemorialCare Health System expect to complete the acquisition in August. Financial terms were not disclosed.
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 26, 2015
16:00 EDTDHROptions Update; June 26, 2015
Subscribe for More Information
12:32 EDTDHRDanaher July options active
Subscribe for More Information
10:04 EDTDHR:High option volume stocks
Subscribe for More Information
June 25, 2015
16:50 EDTDHRDanaher amends, extends split-off exchange offer with NetScout
Danaher (DHR) announced that it has amended and extended by one business day its offer to exchange all outstanding common units of Potomac Holding LLC, a Danaher subsidiary formed to hold Danaher's Communications business, for outstanding shares of Danaher common stock that are validly tendered and not validly withdrawn. The split-off transaction is in connection with the previously announced combination of Danaher's Communications business with NetScout Systems (NTCT). Danaher is amending the offer by: increasing the upper limit on the exchange ratio to 2.4000 Potomac Holding LLC common units per share of Danaher common stock tendered from 2.2522 Potomac Holding LLC common units per share of Danaher common stock tendered; however, the final exchange ratio may be less than the upper limit; extending the Exchange Offer's expiration to 12:00 midnight, New York City time, on July 9, unless extended or terminated, from July 8; and amending the current expected three-day period over which the final exchange ratio will be determined to July 7, 8 and 9, (which previously was expected to be July 6, 7 and 8). The final exchange ratio will be announced by press release by 4:30 p.m., New York City time, on the expiration date. As of June 24, approximately 38,458 shares of Danaher common stock have been tendered.
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
12:52 EDTABTEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
11:41 EDTDHRNetScout shareholders approve proposal to acquire Danaher business
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bathís School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesnít anticipate a sale, the report noted. Reference Link
June 23, 2015
10:00 EDTDGXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:25 EDTDGX, LHPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
06:13 EDTDGXQuest Diagnostics downgraded to Neutral from Buy at Goldman
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use